<DOC>
	<DOCNO>NCT00307294</DOCNO>
	<brief_summary>The primary objective study evaluate PSA response rate combination Doxil Thalidomide patient AIPC fail chemotherapy . Secondary objective include : 1 ) To evaluate clinical response rate combination measurable disease 2 ) To evaluate overall survival combination .</brief_summary>
	<brief_title>Thalidomide Doxil® Patients With Androgen Independent Prostate Cancer ( AIPC )</brief_title>
	<detailed_description>This open label , Phase II trial thalidomide Doxil patient androgen independent prostate cancer rise PSA chemotherapy . The primary objective study evaluate PSA response rate combination Doxil Thalidomide patient AIPC fail chemotherapy . Secondary objective include : 1 ) To evaluate clinical response rate combination measurable disease ( If measurable soft tissue lesion present radiological clinical exam ) ; 2 ) To evaluate overall survival combination . There 18 35 subject least 18 year age enrol single site study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate . Confirmed androgen independent prostate cancer evidence rise PSA ( two successive increase PSA , least 4 week apart ) chemotherapy . If PSA le 5 , increase PSA must least 50 % . Must also castrate testosterone level ( &lt; 50 ng/ml ) Patients could receive 2 previous chemotherapy regimen . No anthracyclines within past 6 month . No prior single agent thalidomide last 12 month . No prior cytotoxic chemotherapy + thalidomide give conjunction Age &gt; 18 year age Performance status ECOG 02 Peripheral neuropathy must &lt; grade 1 Must adequate hematologic , hepatic renal function Men reproductive potential must willing consent use effective contraception treatment least 4 week thereafter Patients must leave ventricular ejection fraction &gt; 50 % within 42 day prior first dose study drug . The method use baseline must use later monitor Must antiandrogen least 46 week ( Flutamide Bicalutamide respectively ) document rise PSA Measurable evaluable disease ( PSA elevation constitute evaluable disease ) . Measurable disease define least one lesion accurately measure least one dimension ( long diameter record ) &gt; 20 mm conventional technique CT scan &gt; 10 mm spiral CT scan . See section 6.B evaluation measurable disease Life expectancy great 3 month Patients must willing able comply FDAmandated S.T.E.P.S.® program Ability understand sign write informed consent approve Institutional Review Board [ IRB/Ethics Committee ] , obtain prior study entry . Patients unstable angina , uncompensated CHF , history MI , PE DVT within last 3 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Androgen</keyword>
	<keyword>AIPC</keyword>
	<keyword>Doxil</keyword>
</DOC>